HD Insights™

Vol. 11 - Spring 2015

Issue link: http://www.e-digitaleditions.com/i/517236

Contents of this Issue

Navigation

Page 1 of 15

H D I N S I G H T S HD Insights, Vol. 11 2 VITAL SIGNS NAME: Frank J. Sasinowski, MS, MPH, JD POSITION: Director, Hyman, Phelps & McNamara, PC; Member, Board of Directors, National Organization for Rare Disorders (NORD) EDUCATION: JD, Georgetown University Law Center; MS, Nutritional Sciences, University of California at Berkeley; MPH, University of California at Berkeley; BS, Biological Sciences and Genetics, Cornell University HOBBIES: Contemplation and meditation (see www.onewednesday.org) Teva/Auspex merger, cont… Copyright © Huntington Study Group 2015. All rights reserved. 1 Teva Reinforces Leadership Position in CNS with Acquisition of Auspex [Internet]. March 30, 2015. Available from: tevapharm.com/news/?itemid=%7BF45C98FD-CEA7-48C4- B9CB-A6BD00D0BEDB%7D. 2 Auspex Pharmaceuticals. Pipeline - Auspex Pharmaceuticals 2015 [May 8, 2015]. Available from: auspexpharma.com/ pipeline/. 3 The Economist. Invent it, swap it or buy it. The Economist. November 15, 2014. Available from: economist.com/news/ business/21632676-why-constant-dealmaking-among- drugmakers-inevitable-invent-it-swap-it-or-buy-it?fsrc=rss 4 Actavis Completes Allergan Acquisition [Internet]. Online; 2015; March 17, 2015. Available from: prnewswire.com/news- releases/actavis-completes-allergan-acquisition-300051633.html 5 Actavis Completes Forest Laboratories Acquisition [Internet]. July 1, 2014. Available from: actavis.com/news/news/ thomson-reuters/actavis-completes-forest-laboratories- acquisition 6 Avanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 Billion [Internet]. Online; December 2, 2014. Available from: prnewswire.com/news-releases/avanir- pharmaceuticals-to-be-acquired-by-otsuka-pharmaceutical- for-35-billion-300003185.html 7 Acorda Therapeutics Completes Acquisition of Civitas Therapeutics [Internet]. Online; 2014; October 22, 2014. Available from: ir.acorda.com/investors/investor-news/ investor-news-details/2014/Acorda-Therapeutics-Completes- Acquisition-of-Civitas-Therapeutics/default.aspx 8 Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc. [Internet]. Online; January 22, 2013. Available from: reuters.com/article/ 2013/01/23/ca-allergan-inc-idUSnBw4rFlD9a +114+BSW20130123 9 Mallinckrodt Announces Definitive Agreement to Acquire CNS Therapeutics, Inc. [Internet]. Online; September 24, 2012. Available from: newsroom.medtronic.com/phoenix.zhtml? c=251324&p=irol-newsArticle&ID=2004166 10 Teva to buy Cephalon for $6.8 billion, tops Valeant [Internet]. Online; May 2, 2011. Available from: reuters.com/article/ 2011/05/02/us-teva-cephalon-idUSTRE74133720110502 11 Biotie to Acquire CNS Therapeutics Firm Synosia in €93.6M All-Shares Deal [Internet]. Online; January 11, 2011. Available from: genengnews.com/gen-news-highlights/biotie-to-acquire- cns-therapeutics-firm-synosia-in-93-6m-all-b-b/81244507/ Table. Selected acquisitions of pharmaceutical firms developing novel central nervous system therapies, 2011-2015 Year Acquirer Target Amount Lead Compound Indication Phase of Development 2015 Actavis[4] Allergan $66 billion OnabotulinumtoxinA (BOTOX®) Variety of neurological and cosmetic indications FDA-approved 2015 Teva[1] Auspex $3.5 billion Dutetrabenazine (SD-809) Huntington disease Pre-NDA 2014 Actavis[5] Forest Laboratories $28 billion Memantine HCl (Namenda™) Moderate to severe dementia from Alzheimer disease FDA-approved 2014 Otsuka[6] Avanir $3.5 billion Dextromethorphan hydrobromide and quinidine sulfate (NUEDEXTA ®) Pseudobulbar affect FDA-approved 2014 Acorda[7] Civitas $525 million Inhaled L-dopa (CVT-301) Parkinson disease Pre-NDA 2013 Allergan[8] MAP $958 million Inhaled dihydroergotamine (Levadex®) Migraines Rejected by FDA in 2014 2012 Mallinckrodt (Covidien)[9] CNS Therapeutics $100 million Baclofen (Gablofen®) Muscle spasms caused by damage to the brain or spinal cord FDA-approved 2011 Teva[10] Cephalon $6.8 billion Modafinil (Provigil ®) Narcolepsy FDA-approved 2011 Biotie[11] Synosia $126 million SYN-115 (Tozadenant) Parkinson disease Pre-NDA Meet the Attorney Mr. Frank Sasinowski has dedicated his career to helping patients and companies bring new therapies for rare diseases to market. He recently shared his work, his hopes for orphan drug development, and his advice for researchers and companies with HD Insights. The following is an edited transcript of the conversation. H D I N S I G H T S

Articles in this issue

Links on this page

Archives of this issue

view archives of HD Insights™ - Vol. 11 - Spring 2015